Capricor Therapeutics Faces Securities Fraud Lawsuit
Rosen Law Firm has filed a class action lawsuit against Capricor Therapeutics for alleged securities fraud. The suit covers purchases made between December 2025 and July 2026.
A class action lawsuit has been filed against Capricor Therapeutics, Inc. (NASDAQ: CAPR) concerning purchases of its securities made between December 17, 2025, and July 26, 2026. The lawsuit was announced by Rosen Law Firm, a global investor rights law firm.
The complaint alleges that Capricor Therapeutics made materially false and misleading statements to investors regarding its development of a treatment for Duchenne muscular dystrophy. Investors who purchased Capricor securities during the specified period are being urged to contact the law firm.
The lawsuit aims to recover losses incurred by investors who purchased securities in the company during the class period. Further details regarding the lawsuit and how to participate are available through Rosen Law Firm.
Capricor Therapeutics is a biotechnology company focused on the development of therapies for cardiovascular and other diseases.